Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Share-based Compensation (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Share-based Compensation for 6 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 84.45% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2025, down 13.06% year-over-year, with the annual reading at $12.5 million for FY2025, 7.27% down from the prior year.
  • Share-based Compensation for Q4 2025 was $2.8 million at Lexicon Pharmaceuticals, up from $1.6 million in the prior quarter.
  • The five-year high for Share-based Compensation was $4.3 million in Q1 2024, with the low at $1.3 million in Q2 2023.
  • Average Share-based Compensation over 3 years is $2.4 million, with a median of $2.2 million recorded in 2025.
  • Peak annual rise in Share-based Compensation hit 144.24% in 2024, while the deepest fall reached 52.15% in 2024.
  • Over 3 years, Share-based Compensation stood at $3.2 million in 2023, then tumbled by 52.15% to $1.5 million in 2024, then skyrocketed by 84.45% to $2.8 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $2.8 million, $1.6 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.